Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.17/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. LMT
10. SBUX

Go back to Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.17/Share

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 26, 2020 4:05 PM EST

Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL

Conference Call Scheduled February 26, 2020 at 4:30 p.m. EDT

BERKELEY HEIGHTS, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business highlights for the... More